{
"info": {
"nct_id": "NCT01004731",
"official_title": "Phase Ib, IIa Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer",
"inclusion_criteria": "* Have a diagnosis of histologically/cytologically confirmed advanced non- small cell lung cancer (NSCLC).\n* Have uni-dimensionally measurable and/or evaluable advanced NSCLC.\n* Have Stage IV or recurrent disease following radiation therapy.\n* Have ECOG performance status of 0-1 or Karnofsky performance status of 80- 100 at study entry.\n* Have given signed informed consent.\n* Be at least 18 years of age.\n* Have ANC greater than or equal to 1,500/mm3, platelets greater than or equal to 100,000/mm3, WBC greater than or equal to 3,000 mm3, and hemoglobin greater than or equal to 9 g/dL.\n* Have total bilirubin less than or equal to 1.5 x upper limits of normal, Alk Phos, AST and ALT less than or equal to 2.5 x upper limits of normal.\n* Have serum creatinine less than or equal to 1.5 mg/dL, or calculated creatinine clearance greater than or equal to 60 cc/minute.\n* Be disease free from a previously treated malignancy for more than three years. Patients with a history or a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix will not be excluded.\n* Agree to use effective contraception if procreative potential exists.\n* Must have positive EGFr expression (tumor tissue) by immunohistochemical assay.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Have received prior murine monoclonal antibody or Cetuximab therapy.\n* Have disease amenable to curative surgery.\n* Have received prior chemotherapy.\n* Have received radiation therapy within 3 weeks prior to the first infusion of Cetuximab.\n* Have a history of clinically significant cardiac disease, serious arrhythmias, or significant conduction abnormalities, in the judgment of the PI.\n* Have uncontrolled seizure disorder, active neurological disease, or Grade 2 or higher neuropathy.\n* Be pregnant or breast-feeding.\n* Have received any investigational agent(s) within 1 month of study entry.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Have a diagnosis of histologically/cytologically confirmed advanced non- small cell lung cancer (NSCLC).",
"criterions": [
{
"exact_snippets": "diagnosis of histologically/cytologically confirmed advanced non- small cell lung cancer (NSCLC)",
"criterion": "non-small cell lung cancer (NSCLC)",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
},
{
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
},
{
"requirement_type": "stage",
"expected_value": "advanced"
}
]
}
]
},
{
"line": "* Have uni-dimensionally measurable and/or evaluable advanced NSCLC.",
"criterions": [
{
"exact_snippets": "uni-dimensionally measurable",
"criterion": "NSCLC",
"requirements": [
{
"requirement_type": "measurement",
"expected_value": "uni-dimensionally measurable"
}
]
},
{
"exact_snippets": "evaluable advanced NSCLC",
"criterion": "NSCLC",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "advanced"
},
{
"requirement_type": "evaluable",
"expected_value": true
}
]
}
]
},
{
"line": "* Have Stage IV or recurrent disease following radiation therapy.",
"criterions": [
{
"exact_snippets": "Stage IV",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "IV"
}
]
},
{
"exact_snippets": "recurrent disease",
"criterion": "disease recurrence",
"requirements": [
{
"requirement_type": "recurrence",
"expected_value": true
}
]
},
{
"exact_snippets": "following radiation therapy",
"criterion": "prior radiation therapy",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": "radiation therapy"
}
]
}
]
},
{
"line": "* Have ECOG performance status of 0-1 or Karnofsky performance status of 80- 100 at study entry.",
"criterions": [
{
"exact_snippets": "ECOG performance status of 0-1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "Karnofsky performance status of 80- 100",
"criterion": "Karnofsky performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 80,
"unit": "N/A"
},
{
"operator": "<=",
"value": 100,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Have given signed informed consent.",
"criterions": [
{
"exact_snippets": "given signed informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "* Be at least 18 years of age.",
"criterions": [
{
"exact_snippets": "at least 18 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Have ANC greater than or equal to 1,500/mm3, platelets greater than or equal to 100,000/mm3, WBC greater than or equal to 3,000 mm3, and hemoglobin greater than or equal to 9 g/dL.",
"criterions": [
{
"exact_snippets": "ANC greater than or equal to 1,500/mm3",
"criterion": "ANC",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "platelets greater than or equal to 100,000/mm3",
"criterion": "platelets",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "WBC greater than or equal to 3,000 mm3",
"criterion": "WBC",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 3000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "hemoglobin greater than or equal to 9 g/dL",
"criterion": "hemoglobin",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 9,
"unit": "g/dL"
}
}
]
}
]
},
{
"line": "* Have total bilirubin less than or equal to 1.5 x upper limits of normal, Alk Phos, AST and ALT less than or equal to 2.5 x upper limits of normal.",
"criterions": [
{
"exact_snippets": "total bilirubin less than or equal to 1.5 x upper limits of normal",
"criterion": "total bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "x upper limits of normal"
}
}
]
},
{
"exact_snippets": "Alk Phos ... less than or equal to 2.5 x upper limits of normal",
"criterion": "Alk Phos",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "x upper limits of normal"
}
}
]
},
{
"exact_snippets": "AST ... less than or equal to 2.5 x upper limits of normal",
"criterion": "AST",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "x upper limits of normal"
}
}
]
},
{
"exact_snippets": "ALT less than or equal to 2.5 x upper limits of normal",
"criterion": "ALT",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "x upper limits of normal"
}
}
]
}
]
},
{
"line": "* Have serum creatinine less than or equal to 1.5 mg/dL, or calculated creatinine clearance greater than or equal to 60 cc/minute.",
"criterions": [
{
"exact_snippets": "serum creatinine less than or equal to 1.5 mg/dL",
"criterion": "serum creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "calculated creatinine clearance greater than or equal to 60 cc/minute",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "cc/minute"
}
}
]
}
]
},
{
"line": "* Be disease free from a previously treated malignancy for more than three years. Patients with a history or a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix will not be excluded.",
"criterions": [
{
"exact_snippets": "disease free from a previously treated malignancy for more than three years",
"criterion": "previously treated malignancy",
"requirements": [
{
"requirement_type": "disease-free duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "years"
}
}
]
},
{
"exact_snippets": "history or a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix will not be excluded",
"criterion": "history of basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": false
}
]
}
]
},
{
"line": "* Agree to use effective contraception if procreative potential exists.",
"criterions": [
{
"exact_snippets": "Agree to use effective contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "agreement",
"expected_value": true
}
]
},
{
"exact_snippets": "procreative potential exists",
"criterion": "procreative potential",
"requirements": [
{
"requirement_type": "existence",
"expected_value": true
}
]
}
]
},
{
"line": "* Must have positive EGFr expression (tumor tissue) by immunohistochemical assay.",
"criterions": [
{
"exact_snippets": "positive EGFr expression (tumor tissue) by immunohistochemical assay",
"criterion": "EGFr expression",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "positive"
},
{
"requirement_type": "method",
"expected_value": "immunohistochemical assay"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Have received prior murine monoclonal antibody or Cetuximab therapy.",
"criterions": [
{
"exact_snippets": "Have received prior murine monoclonal antibody",
"criterion": "prior murine monoclonal antibody therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Have received prior ... Cetuximab therapy",
"criterion": "prior Cetuximab therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Have disease amenable to curative surgery.",
"criterions": [
{
"exact_snippets": "disease amenable to curative surgery",
"criterion": "disease",
"requirements": [
{
"requirement_type": "amenability to curative surgery",
"expected_value": true
}
]
}
]
},
{
"line": "* Have received prior chemotherapy.",
"criterions": [
{
"exact_snippets": "Have received prior chemotherapy.",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
}
]
},
{
"line": "* Have received radiation therapy within 3 weeks prior to the first infusion of Cetuximab.",
"criterions": [
{
"exact_snippets": "received radiation therapy within 3 weeks prior to the first infusion of Cetuximab",
"criterion": "radiation therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Have a history of clinically significant cardiac disease, serious arrhythmias, or significant conduction abnormalities, in the judgment of the PI.",
"criterions": [
{
"exact_snippets": "clinically significant cardiac disease",
"criterion": "cardiac disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "clinically significant"
}
]
},
{
"exact_snippets": "serious arrhythmias",
"criterion": "arrhythmias",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "serious"
}
]
},
{
"exact_snippets": "significant conduction abnormalities",
"criterion": "conduction abnormalities",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "significant"
}
]
}
]
},
{
"line": "* Have uncontrolled seizure disorder, active neurological disease, or Grade 2 or higher neuropathy.",
"criterions": [
{
"exact_snippets": "uncontrolled seizure disorder",
"criterion": "seizure disorder",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "active neurological disease",
"criterion": "neurological disease",
"requirements": [
{
"requirement_type": "activity status",
"expected_value": "active"
}
]
},
{
"exact_snippets": "Grade 2 or higher neuropathy",
"criterion": "neuropathy",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "Grade"
}
}
]
}
]
},
{
"line": "* Be pregnant or breast-feeding.",
"criterions": [
{
"exact_snippets": "Be pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "breast-feeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Have received any investigational agent(s) within 1 month of study entry.",
"criterions": [
{
"exact_snippets": "Have received any investigational agent(s) within 1 month of study entry.",
"criterion": "investigational agent(s)",
"requirements": [
{
"requirement_type": "time since last administration",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "month"
}
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}